Last update 08 May 2025

Elraglusib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Action
inhibitors
Mechanism
GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationRare Pediatric Disease (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H13FN2O5
InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-N
CAS Registry1034895-42-5

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Hodgkin's lymphoma refractoryPhase 2
United States
04 Jan 2019
Non-Hodgkin's lymphoma refractoryPhase 2
France
04 Jan 2019
Non-Hodgkin's lymphoma refractoryPhase 2
Belgium
04 Jan 2019
Non-Hodgkin's lymphoma refractoryPhase 2
Canada
04 Jan 2019
Non-Hodgkin's lymphoma refractoryPhase 2
Portugal
04 Jan 2019
Non-Hodgkin's lymphoma refractoryPhase 2
Spain
04 Jan 2019
Colorectal CancerPhase 2--
Colorectal CancerPhase 2--
Renal Cell CarcinomaPhase 2--
Renal Cell CarcinomaPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Salivary Gland Neoplasms
tumor PD-L1 | GSK-3β expression
32
(hgzyagwbrz) = frfccvipsc hshamcwmvd (hckrjeausf, 2 - 25)
Positive
29 Apr 2025
Phase 2
286
Elraglusib + gemcitabine/nab-paclitaxel
(qwptfalakv) = ffxprsihda ulkaypjtwi (uyvndmvcas )
Met
Positive
17 Dec 2024
gemcitabine/nab-paclitaxel
(qwptfalakv) = cqtviikyrb ulkaypjtwi (uyvndmvcas )
Met
Phase 2
42
(nqceqdkqpv) = uedatxigxn dgtiwtqstt (ernpannlmi, 32.5 - 70.6)
Positive
26 May 2023
Phase 1/2
Advanced cancer
Third line
-
(melanoma)
(laznpqshqv) = euseuxujwk kwfmlckbbz (enepzstsxn )
Positive
14 Apr 2023
(colorectal cancer)
(gaecsujqnc) = mkmmffwxcr ajwtessatf (koyzpqfunt )
Phase 1/2
23
ElraglusibElraglusib alone or in combination with chemotherapy
(sqjensmvwc) = none vvjslrurwe (irrswanuhm )
Positive
02 Jun 2022
Phase 1/2
18
(blytjlsczn) = mild vision changes 50%, infusion reactions 22% liwnyladtt (nivdmutkhd )
Positive
07 Feb 2022
Phase 1/2
Glioma
IDH | 1p19q | MGMT ...
18
andhlxkogv(cndfxngctv) = tbeaqzscka lbwncbfkky (dpfusewvvs )
Positive
12 Nov 2021
tmixrqbauk(hoyrbivjmi) = oacvntzsdi dnmbkufkmx (rkzvulrsts )
Not Applicable
-
iwllmjmpze(hyljwbwnat) = hiwdnpsxpk lbcmqgmwhc (xiwpabaasr )
-
01 Jul 2021
Phase 1/2
227
(mfwkijwllx) = rrodvempyw zgvuyhxsbf (pgfclfvmht )
Positive
28 May 2021
Phase 1
101
(zwciuedyhm) = n = 14 hconcfxvql (nytrnbtbee )
Positive
25 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free